The offering totals $254,880,000 before fees, and Seaport expects net proceeds of about $233.9 million. Entities affiliated with General Atlantic, a holder of more than 5% of the stock, have indicated interest in up to $50 million of shares, which is not binding.
Seaport Therapeutics filed its Form S-1 on April 10, 2026 with the share count and price range still blank. The filing shows a 2025 net loss of $74,881 thousand and a stockholders' deficit of $92,545 thousand.
Questions about Seaport Therapeutics
When did Seaport Therapeutics go public?
Our latest story on this, dated May 1, 2026: "Seaport Therapeutics prices IPO of 14,160,000 shares at $18.00". The story links the filing or release it is based on. Read the story.
Has Seaport Therapeutics raised money recently?
Our latest story on this, dated May 1, 2026: "Seaport Therapeutics prices IPO of 14,160,000 shares at $18.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Seaport Therapeutics?
Seaport Therapeutics, Inc. trades under the ticker SPTX on NASDAQ.
Where is Seaport Therapeutics listed?
Seaport Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Seaport Therapeutics?
The SEC Central Index Key (CIK) for Seaport Therapeutics, Inc. is 2042347. Its filings are on SEC EDGAR.
How many shares does Seaport Therapeutics have outstanding?
53,530,550 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-08-03.
Which country or territory is Seaport Therapeutics listed under?
Our directory records Seaport Therapeutics, Inc. under United States.
What does Seaport Therapeutics do?
Our directory classifies Seaport Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Seaport Therapeutics?
The ISIN recorded for Seaport Therapeutics, Inc. is US81221K1088.
Does aibio.space cover Seaport Therapeutics?
aibio.space lists Seaport Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Seaport Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Seaport Therapeutics (SPTX) stock news?
Our latest story on Seaport Therapeutics, dated May 1, 2026: "Seaport Therapeutics prices IPO of 14,160,000 shares at $18.00". The offering totals $254,880,000 before fees, and Seaport expects net proceeds of about $233.9 million. Entities affiliated with General Atlantic, a holder of more than 5% of the stock, have indicated interest in up to $50 million of shares, which is not binding. Source.
How much cash does Seaport Therapeutics have?
From our story of Apr 10, 2026: At December 31, 2025, cash, cash equivalents and investments were $233,653 thousand, the accumulated deficit was $114,109 thousand and total stockholders' deficit was $92,545 thousand. Source.
Is Seaport Therapeutics a smaller reporting company?
SEC records list Seaport Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.
Where is Seaport Therapeutics headquartered?
SEC records list its business address as 6 TIDE STREET, BOSTON, MA, 02110.
Investor discussion: Seaport Therapeutics
Members talk about Seaport Therapeutics (SPTX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Seaport Therapeutics, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SPTX on TradingView.
SEC filings and registration
SEC name
Seaport Therapeutics, Inc.
CIK
2042347
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
SPTX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
6 TIDE STREET, BOSTON, MA, 02110
Phone
617-807-4062
Shares outstanding
53,530,550 as of 2026-07-27 (10-Q filed 2026-08-03)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Seaport Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SPTX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio